Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465717 | 0.74 | KDR (0.35) | KEAP1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL27297870 | 0.70 | KDR (0.36) | ALDH1A1 | |
| SCHEMBL5465794 | 0.69 | KDR (0.35) | KEAP1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5465714 | 0.68 | — | — | |
| SCHEMBL17393052 | 0.64 | ALDH1A1 (0.43) | KEAP1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5459528 | 0.64 | DPP4 (0.31) | ALDH1A1 | |
| SCHEMBL11392636 | 0.64 | TSHR (0.35) | KEAP1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL15515230 | 0.63 | KEAP1 (0.42) | KEAP1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10916903 | 0.63 | KDM4E (0.55) | KEAP1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL416345 | 0.63 | SMN1; SMN2 (0.50) | KEAP1SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043010-A1 | Quinazoline derivatives | ASTRAZENECA UK LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043010-A1 | Quinazoline derivatives | ERBB2, ABL1, EGFR | KEAP1 1006/4885SMN1; SMN2 4581/4885KDM4E 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.